Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) (H11)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01652261 |
Recruitment Status :
Withdrawn
(Study closed due to lack of recruitment)
First Posted : July 30, 2012
Last Update Posted : February 15, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hodgkin Lymphoma | Drug: ABVD + FDG-PET/CT Scan treatment adaptation Drug: BEACOPPesc | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group |
Actual Study Start Date : | May 2013 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: experimental arm
An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment. Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es)). |
Drug: ABVD + FDG-PET/CT Scan treatment adaptation Drug: BEACOPPesc |
Active Comparator: standard arm
A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment. Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es)). |
Drug: BEACOPPesc |
- Freedom from treatment failure [ Time Frame: 9 years after first patient in (FPI) ]
- response at the end of therapy [ Time Frame: 9 years after FPI ]
- Progression-free survival [ Time Frame: 9 years after FPI ]
- Overall survival [ Time Frame: 9 years after FPI ]
- Acute toxicity [ Time Frame: 9 years after FPI ]
- Hematological toxicity (blood cell count) can be significant especially for patients who will receive BEACOPPesc .
- Bleomycine interstitial pneumonitis has been frequently reported and requires the immediate stop of further bleomycine administration.
- Rarely, procarbazine allergy and intolerance has been reported.
- Nausea & vomiting due to cyclophosphamide, doxorubicin, dacarbazine and procarbazine may be significant.
- Total reversible alopecia occurs in most cases.
- Escalated BEACOPP-related toxic deaths have been reported but do not exceed those observed with standard ABVD.
- Long-term toxicity in terms of second malignancies, cardiovascular and pulmonary events [ Time Frame: 9 years after FPI ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
- Previously untreated, histologically proven classical Hodgkin lymphoma
- Clinical stages III/IV (Ann Arbor)
- Age 18-60
- WHO performance 0-2
- Adequate organ function
- Patients of childbearing/reproductive potential should use adequate birth control measures during the whole duration of study treatment.
- Written informed consent according to ICH/EU Good Clinical Practice, and national/local regulations
Exclusion criteria:
- Pregnancy or lactation
- Specific contraindications to BEACOPPesc therapy, including:
- Poorly controlled diabetes mellitus
- HIV infection,
- Chronic active hepatitis B and/or hepatitis C
- Concomitant or previous malignancies with the exception of basal cell skin tumors, adequately treated carcinoma in situ of the cervix and any cancer that has been in complete remission for >5 years
- Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01652261
Denmark | |
Rigshospitalet | |
Copenhagen, Denmark, 2100 |
Study Chair: | Martin Hutchings | Rigshospitalet, Denmark | |
Study Chair: | Berthe Aleman | The Netherlands Cancer Institute, Amsterdam, The Netherlands | |
Study Chair: | Gustaaf van IMHOFF | University Medical Center Groningen | |
Study Chair: | Wim Oyen | Radboud University Medical Center |
Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
ClinicalTrials.gov Identifier: | NCT01652261 |
Other Study ID Numbers: |
EORTC-20101-23101 2011-005473-22 ( EudraCT Number ) |
First Posted: | July 30, 2012 Key Record Dates |
Last Update Posted: | February 15, 2021 |
Last Verified: | June 2014 |
advanced stage |
Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |